In April, when hearing aid group Demant announced its intention to sell its 15-year-old Hearing Implants business, also known as Oticon Medical, to Australian Cochlear, no one knew whether the business leg was running a profit or a loss.
Demant was only willing to talk top-line figures at the time, but in Tuesday’s second quarterly report, the company finally revealed precise figures for how well the discontinued operation has performed.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Jefferies spots weaknesses in GN
One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
Fujifilm doubles bottom line in annual report
Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.
FDA fast-tracks Eli Lilly's obesity candidate
Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.
Clinical Project Lead 
Clinical Trial Supplies Senior Professional 
CMC Writer 
CTM / Junior CTM Biotech 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Chief Business Officer 
Product specialist 
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Pharmacovigliance (Associate) Director or Senior Specialist 
Scientist Radiochemistry 
Orifarm Healthcare Product Development PMO Director 
KLIFO is looking for a Senior QA Specialist GMP for our Glostrup office 
Drug Safety Associate 
Senior/lead consultant at Emendo Engineering